1. Home
  2. DLX vs RAPP Comparison

DLX vs RAPP Comparison

Compare DLX & RAPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Deluxe Corporation

DLX

Deluxe Corporation

HOLD

Current Price

$27.80

Market Cap

1.3B

ML Signal

HOLD

RAPP

Rapport Therapeutics Inc.

HOLD

Current Price

$27.09

Market Cap

1.2B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
DLX
RAPP
Founded
1915
2022
Country
United States
United States
Employees
N/A
N/A
Industry
Advertising
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.2B
IPO Year
N/A
2024

Fundamental Metrics

Financial Performance
Metric
DLX
RAPP
Price
$27.80
$27.09
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
6
Target Price
$23.00
$47.00
AVG Volume (30 Days)
616.0K
337.3K
Earning Date
01-28-2026
03-10-2026
Dividend Yield
4.32%
N/A
EPS Growth
58.58
N/A
EPS
1.80
N/A
Revenue
$2,133,200,000.00
N/A
Revenue This Year
$1.16
N/A
Revenue Next Year
$1.90
N/A
P/E Ratio
$15.44
N/A
Revenue Growth
0.54
N/A
52 Week Low
$13.61
$6.43
52 Week High
$28.60
$42.27

Technical Indicators

Market Signals
Indicator
DLX
RAPP
Relative Strength Index (RSI) 71.40 48.33
Support Level $23.89 $25.21
Resistance Level $28.60 $28.59
Average True Range (ATR) 0.96 1.53
MACD 0.29 0.01
Stochastic Oscillator 92.32 52.96

Price Performance

Historical Comparison
DLX
RAPP

About DLX Deluxe Corporation

Deluxe Corporation is principally a payments and data company. Its reportable segments are; Merchant Services, B2B Payments, Data Solutions, and Print. Maximum revenue is derived from its Print segment which provides printed personal and business checks, business essentials, as well as branded promotional, print, apparel, and digital storefront solutions. The Merchant Services segment provides electronic credit and debit card authorization, payment systems, and processing services. The B2B segment offers treasury management solutions, integrated accounts payable disbursements, and fraud and security services, and the Data Solutions segment offers data, analytics, and marketing services as well as financial institution profitability reporting and business incorporation services.

About RAPP Rapport Therapeutics Inc.

Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.

Share on Social Networks: